Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Primary Lung Cancer in Recipients of Lung Transplant
Background: Lung transplantation is a life-saving treatment for patients with end stage lung disease. There may be a higher incidence of lung cancer in lung transplant recipients, and these cancers tend to be diagnosed in a more advanced stage. There is very little data on the safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) for lesions in the native lung in lung-transplant recipients.
Materials and Methods: A retrospective chart review of all patients who have undergone lung transplantation and treated with SBRT for lung cancer in the native lung in the Davidoff Cancer Center.
Results: Four patients who were treated with SBRT to a total of 5 lesions were included. Two patients were treated without histological confirmation of malignancy. All cases were discussed in a multidisciplinary team before being referred for radiotherapy. Standard SBRT dosing was used. Responses were achieved by imaging in all cases – 3 lesions exhibited a complete response and two lesions partial responses. The patients who had partial responses developed distant metastases and died shortly. No patient developed measurable toxicity.
Conclusions: SBRT is effective and safe for the management of lung cancer in lung-transplanted patients. Standard dose and fractionation can be used.
Copyright (c) 2020 Radiology and Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
License to Publish
Please read the terms of this agreement, print, initial page 1, sign page 3, scan and send the document as one file attached to an e-mail to email@example.com